Dr. Fatima Nogueira
'%3e%3cpath%20d='M22.1642%2019.0924C21.7317%2018.068%2021.1041%2017.1375%2020.3163%2016.3527C19.5309%2015.5656%2018.6006%2014.9381%2017.5766%2014.5048C17.5674%2014.5002%2017.5582%2014.4979%2017.5491%2014.4933C18.9774%2013.4616%2019.9059%2011.7811%2019.9059%209.88504C19.9059%206.74408%2017.3611%204.19922%2014.2201%204.19922C11.0792%204.19922%208.53429%206.74408%208.53429%209.88504C8.53429%2011.7811%209.46282%2013.4616%2010.8912%2014.4956C10.882%2014.5002%2010.8728%2014.5025%2010.8636%2014.5071C9.83652%2014.9404%208.91487%2015.5617%208.1239%2016.355C7.33685%2017.1404%206.70933%2018.0707%206.276%2019.0947C5.85031%2020.0972%205.62072%2021.172%205.59967%2022.2609C5.59905%2022.2853%205.60335%2022.3097%205.61229%2022.3325C5.62123%2022.3553%205.63465%2022.376%205.65174%2022.3935C5.66883%2022.4111%205.68926%2022.425%205.71182%2022.4345C5.73437%2022.444%205.7586%2022.4489%205.78308%2022.4489H7.15868C7.25956%2022.4489%207.3398%2022.3686%207.3421%2022.2701C7.38795%2020.5001%208.09868%2018.8425%209.35506%2017.5861C10.655%2016.2862%2012.3814%2015.5709%2014.2201%2015.5709C16.0588%2015.5709%2017.7852%2016.2862%2019.0852%2017.5861C20.3415%2018.8425%2021.0523%2020.5001%2021.0981%2022.2701C21.1004%2022.3709%2021.1807%2022.4489%2021.2815%2022.4489H22.6571C22.6816%2022.4489%2022.7058%2022.444%2022.7284%2022.4345C22.751%2022.425%2022.7714%2022.4111%2022.7885%2022.3935C22.8056%2022.376%2022.819%2022.3553%2022.8279%2022.3325C22.8369%2022.3097%2022.8412%2022.2853%2022.8406%2022.2609C22.8176%2021.165%2022.5907%2020.0989%2022.1642%2019.0924ZM14.2201%2013.8284C13.1678%2013.8284%2012.1773%2013.418%2011.4322%2012.6729C10.6871%2011.9278%2010.2767%2010.9374%2010.2767%209.88504C10.2767%208.83271%2010.6871%207.84227%2011.4322%207.09715C12.1773%206.35204%2013.1678%205.94165%2014.2201%205.94165C15.2724%205.94165%2016.2629%206.35204%2017.008%207.09715C17.7531%207.84227%2018.1635%208.83271%2018.1635%209.88504C18.1635%2010.9374%2017.7531%2011.9278%2017.008%2012.6729C16.2629%2013.418%2015.2724%2013.8284%2014.2201%2013.8284Z'%20fill='%238590A2'/%3e%3c/g%3e%3c/svg%3e)
Co-authors
Following
Followers
Research Focus & Metrics
Explore full metrics on Scilit
Academic Career Length
29Years (1998-Present)
(Calculated once Scilit publication data is synced: current year − year of first publication + 1)
Representative Publications
View All Publications1 January 2014 in Antimicrobial Agents and Chemotherapy
Journal Article
MMMarly M. Marques
Marly M. Marques
MCMonica R. F. Costa
Monica R. F. Costa
FFFranklin S. Santana Filho
Franklin S. Santana Filho
JVJosé L. F. Vieira
José L. F. Vieira
MNMargareth T. S. Nascimento
Margareth T. S. Nascimento
MAMaria G. C. Alecrim
Maria G. C. Alecrim
+6
Data on chloroquine (CQ)-resistantPlasmodium vivaxin Latin America is limited, even with the current research efforts to sustain an efficient malaria control program in all these countries whereP. vivaxis endemic and where malaria still is a major public health issue. This study estimatedin vivoCQ resistance in patients with uncomplicatedP. vivaxmalaria, with use of CQ and primaquine simultaneously, in the Brazilian Amazon. Of a total of 135 enrolled subjects who accomplished the 28-day follow-up, parasitological failure was observed in 7 (5.2%) patients, in whom plasma CQ and desethylchloroquine (DCQ) concentrations were above 100 ng/dl. Univariate analysis showed that previous exposure to malaria and a higher initial mean parasitemia were associated with resistance but not with age or gender. In the multivariate analysis, only high initial parasitemia remained significant. Hemoglobin levels were similar at the beginning of the follow-up and were not associated with parasitemia. However, at day 3 and day 7, hemoglobin levels were significantly lower in patients presenting CQ resistance. TheP. vivaxdhfr(pvdhfr),pvmrp1,pvmdr1, andpvdhpsgene mutations were not related to resistance in this small sample.P. vivaxCQ resistance is already a problem in the Brazilian Amazon, which could be to some extent associated with the simultaneous report of anemia triggered by this parasite, a common complication of the disease in most of the areas of endemicity.
1 June 2014 in European Journal of Medicinal Chemistry
Journal Article
MCMarta P. Carrasco
Marta P. CarrascoANAna S. Newton
Ana S. Newton
Luís Miguel GoncalvesAGAna Góis
Ana Góis
MMMarta Machado
Marta Machado
RMRui Moreira
Rui Moreira +6
1 April 2003 in Molecular and Cellular Probes
Journal Article
JGJ.P. Gil
J.P. GilFatima NogueiraJSJ. Strömberg-Nörklit
J. Strömberg-Nörklit
JLJ. Lindberg
J. Lindberg
MCM. Carrolo
M. Carrolo
VRV.E. Rosário
V.E. Rosário
+4
1 May 2004 in Infection and Immunity
Journal Article
SBSébAstien Bagot
SébAstien Bagot
Fatima NogueiraACAlexis Collette
Alexis Collette
VRVirgilio Do Rosario
Virgilio Do Rosario
FLFrançoIs Lemonier
FrançoIs Lemonier
ILInès Leleu
Inès Leleu +1
To obtain insight into the mechanisms that contribute to the pathogenesis ofPlasmodiuminfections, we developed an improved rodent model that mimics human malaria closely by inducing cerebral malaria (CM) through sporozoite infection. We used this model to carry out a detailed study on isolated T cells recruited from the brains of mice during the development of CM. We compared several aspects of the immune response related to the experimental model ofPlasmodium bergheiANKA infection induced by sporozoites in C57BL/6 mice and those related to a blood-stage infection. Our data show that in both models, oligoclonal TCRVβ4+, TCRVβ6+, TCRVβ8.1+, and TCRVβ11+major histocompatibility complex class I-restricted CD8 T cells were present in the brains of CM+mice. These CD8+T cells display an activated phenotype, do not undergo apoptosis, secrete gamma interferon or tumor necrosis factor alpha, and are associated with the development of the neurological syndrome.
23 December 2013 in ACS Medicinal Chemistry Letters
Journal Article
DMDaniela Miranda
Daniela Miranda
RCRita Capela
Rita CapelaIAInês S. Albuquerque
Inês S. AlbuquerquePMPatrícia Meireles
Patrícia Meireles
IPIsa Paiva
Isa Paiva
FLFrancisca Lopes
Francisca Lopes +10
19 March 2015 in PLOS ONE
Journal Article
CECarlos Escobar
Carlos Escobar
SPSara Pateira
Sara Pateira
ELElsa Lobo
Elsa Lobo
LLLis Lobo
Lis LoboRTRosa Teodósio
Rosa TeodósioFatima Nogueira +4
We report the presence of SNPs in Plasmodium falciparum K13-propeller gene in two African countries, Angola and Mozambique, where malaria is a serious public health problem. Samples were collected before and after ACT introduction as first-line treatment. In each country 50 samples collected before and 50 after ACT introduction were analysed. A total of three different mutations (R471R and R575R in Angola and V494I in Mozambique) were identified in five samples, all collected after the introduction of ACT. The R471R mutation detected in Angola has already been reported in Africa (DR-Congo and Gabon). However, the mutations R575R (Angola) and V494I (Mozambique), have never been reported. V494I is adjacent to the known K13 resistance-associated mutation Y493H, although functional analysis did not predict a deleterious effect on protein function.
About Me
Fatima Nogueira is a Principal Investigator (https://www.cienciavitae.pt/7B1B-1ABB-1A16) at the Medical Parasitology UNIT, IHMT-NOVA. Graduated in Molecular Microbiology and Genetics, the University of Lisbon, and holds a Master's in Medical Parasitology and a PhD in Biomedical Sciences, with a specialty of Medical Parasitology, from IHMT-NOVA. Research interests: antimalarial drug resistance mechanisms and targets; searching for synthetic and natural compounds as new antimalarials; and the development of molecular tools for monitoring drug resistance in Plasmodium spp. Holds two patents. Integrated member of GHTM&LA-REAL and a collaborator member of LAQV-REQUIMTE. Technical scientific support (advisor) at i) the Molecular Biology Laboratory of Lubango Central Hospital (LBM-HCL), Angola, since 2022. Editor of the Anti-Infective Agents section of Frontiers in Drug Design and of Discovery and Molecular Sciences: Molecular Pharmacology (MDPI). Has co-authored over 106 papers in internationally indexed scientific journals, in the fields of malaria drug resistance and new antimalarials. Regularly maintains field research collaboration and training with CPLP countries, Senegal and Thailand. Scientific advisory board member of the PhD program Global Health and Infectious Diseases at IHMT-NOVA. Coordinates four curricular units (two PhD and two MSc) in programs at IHMT-NOVA. Supervisor of ten PhD students (six ongoing) and twenty-six MSc students (twenty-two completed, four ongoing).